1st ESMO consensus conference in lung cancer; Lugano 2010: Small-cell lung cancer

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 1973-1980

  Stahel, R ^a   Thatcher, N ^b   Fruh M ^c   Le Pechoux C ^d   Postmus, P E ^e   Sorensen, J B ^f   Felip, E ^g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Rigshospitalet   (Denmark)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Consensus; ESMO; SCLC

Indexed keywords

AMRUBICIN; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; PLATINUM; TOPOTECAN;

ADVANCED CANCER; ALGORITHM; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONSENSUS; CONSENSUS DEVELOPMENT; EARLY CANCER; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDIASTINUM CANCER; MEDICAL EXPERT; MEDICAL PERSONNEL; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; SWITZERLAND;

EID: 80052425152     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr313     Document Type: Article

References (42)

1. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
2. Sorensen M, Pijls-Johannasma M, Felip E. On behalf of the ESMO Guidelines Working Group. Small-cell-lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2010; 21 (Suppl 5): v120-v125.
3. Shepherd FA, Crowley J, Van Houtte P et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2: 1067-1077.
4. Detterbeck FC, Boffa DJ, Tanoue LT, Wilson LD. Details and difficulties regarding the new lung cancer staging system. Chest 2010; 137: 1172-1180.
5. Bradley JD, Dehdashti F, Mintun MA et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22: 3248-3254.
6. Fischer BM, Mortensen J, Langer SW et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18: 338-345.
7. Niho S, Fujii H, Murakami K et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57: 328-333.
8. Vinjamuri M, Craig M, Campbell-Fontaine A et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008; 9: 30-34.
9. Badzio A, Kurowski K, Karnicka-Mlodkowska H et al. A retrospective comparative study of surgery followed by chemotherapy vs non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 2004; 26: 183-188.
10. Yu JB, Decker RH, Detterbeck FC et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010; 5: 215-219.
11. Schreiber D, Rineer J, Weedon J et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010; 116: 1350-1357.
12. Jiang J, Liang X, Zhou X et al. Meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol 2010; 5: 867-873.
13. Zatloukal P, Cardenal F, Szczesna A et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21: 1810-1816.
14. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time. between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 1057-1563.
15. Marks LB, Bentzen SM, Deasy JO et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010; 76 (3 Suppl): S70-S76.
16. De Ruysscher D, Faivre-Finn C, Nestle U. on behalf of the Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). EORTC recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. J Clin Oncol 2010; 28: 5301-5310.
17. Baas P, Belderbos JS, Senan S et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer 2006; 94: 625-630.
18. De Ruysscher D, Bremer RH, Koppe F et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 2006; 80: 307-312.
19. van Loon J, De Ruysscher D, Wanders R et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77: 329-336.
20. Quon H, Shepherd FA, Payne DG et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43: 39-45.
21. Yuen AR, Zou G, Turrisi AT et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89: 1953-1960.
22. Shimizu T, Sekine I, Sumi M et al. Concurrent chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older. Jpn J Clin Oncol 2007; 37: 181-185.
23. Jeremic B, Shibamoto Y, Nikolic N et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17: 2092-2099.
24. Kochhar R, Frytak S, Shaw EG et al. Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol 1997; 20: 125-127.
25. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-484.
26. Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-672.
27. Le Pechoux C, Dunant A, Senan S et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10: 467-474.
28. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994; 12: 627-642.
29. Wolfson AH, Bae K, Komaki R et al. Secondary endpoints of a phase II randomized trial (RTOG 0212): impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 75 (Suppl 1): S34.
30. Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer. A systematic review and practice guidelines. J Thorac Oncol 2007; 2: 348-354.
31. O'Brien M, Ciuleanu T, Tsekov H et al. Phase III trial comparing supportive care alone with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447.
32. Von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1990; 17: 658-667.
33. Eckardt JR, von Pawel J, Pujol JL et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25: 2086-2092.
34. Von Pawel J, Gatzemeier U, Pujol JL et al. Phase II comparator study of oral vs. intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743-1749.
35. Ihde DC, Bilek FS, Cohen MH et al. Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy. Radiology 1979; 132: 443-446.
36. Ochs JJ, Tester WJ, Cohen MH et al. "Salvage" radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 1983; 67: 1123-1126.
37. Salazar OM, Yee GJ, Slawson RG. Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer. Int J Radiat Oncol Biol Phys 1991; 21: 645-650.
38. Sadikov E, Bezjak A, Yi QL et al. Value of whole brain re-irradiation for brain metastases-single centre experience. Clin Oncol (R Coll Radiol) 2007; 19: 532-538.
39. Hazel van GA, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small-cell cancer of the lung. Cancer 1983; 51: 933-937.
40. Sheehan J, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 2005; 102 (Suppl): 247-254.
41. Ammirati M, Cobbs CS, Linskey ME et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 85-96.
42. Albain KS, Crowley JJ, Hutchins L et al. Predictors of survival following relapse or progression of small cell lung cancer Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993; 15: 1184-1191.